AAAAAA

   
Results: 1-4 |
Results: 4
ECONOMIC-EVALUATION OF CHEMOTHERAPY WITH MITOXANTRONE PLUS PREDNISONEFOR SYMPTOMATIC HORMONE-RESISTANT PROSTATE-CANCER - BASED ON A CANADIAN RANDOMIZED TRIAL WITH PALLIATIVE END-POINTS
Authors: BLOOMFIELD DJ KRAHN MD NEOGI T PANZARELLA T SMITH TJ WARDE P WILLAN AR ERNST S MOORE MJ NEVILLE A TANNOCK IF
Citation: Dj. Bloomfield et al., ECONOMIC-EVALUATION OF CHEMOTHERAPY WITH MITOXANTRONE PLUS PREDNISONEFOR SYMPTOMATIC HORMONE-RESISTANT PROSTATE-CANCER - BASED ON A CANADIAN RANDOMIZED TRIAL WITH PALLIATIVE END-POINTS, Journal of clinical oncology, 16(6), 1998, pp. 2272-2279
SHOULD BISPHOSPHONATES BE PART OF THE STANDARD THERAPY OF PATIENTS WITH MULTIPLE-MYELOMA OR BONE METASTASES FROM OTHER CANCERS - AN EVIDENCE-BASED REVIEW
Authors: BLOOMFIELD DJ
Citation: Dj. Bloomfield, SHOULD BISPHOSPHONATES BE PART OF THE STANDARD THERAPY OF PATIENTS WITH MULTIPLE-MYELOMA OR BONE METASTASES FROM OTHER CANCERS - AN EVIDENCE-BASED REVIEW, Journal of clinical oncology, 16(3), 1998, pp. 1218-1225
ECONOMIC-EVALUATION OF CHEMOTHERAPY WITH MITOXANTRONE PLUS PREDNISONEFOR SYMPTOMATIC HORMONE-RESISTANT PROSTATE-CANCER BASED ON A CANADIANRANDOMIZED TRIAL WITH PALLIATIVE END-POINTS
Authors: BLOOMFIELD DJ KRAHN MD WILLAN AR TANNOCK IF
Citation: Dj. Bloomfield et al., ECONOMIC-EVALUATION OF CHEMOTHERAPY WITH MITOXANTRONE PLUS PREDNISONEFOR SYMPTOMATIC HORMONE-RESISTANT PROSTATE-CANCER BASED ON A CANADIANRANDOMIZED TRIAL WITH PALLIATIVE END-POINTS, European journal of cancer, 33, 1997, pp. 5-5
THE DEVELOPMENT OF EVIDENCE BASED GUIDELINES FOR THE USE OF BIPHOSPHONATES IN BONE METASTASES OR MULTIPLE-MYELOMA
Authors: BLOOMFIELD DJ
Citation: Dj. Bloomfield, THE DEVELOPMENT OF EVIDENCE BASED GUIDELINES FOR THE USE OF BIPHOSPHONATES IN BONE METASTASES OR MULTIPLE-MYELOMA, British Journal of Cancer, 74, 1996, pp. 32-32
Risultati: 1-4 |